KalVista licenses sebetralstat Japan rights to Kaken; $11M upfront, up to $24M total plus royalties

KalVista Pharmaceuticals, Inc.

Upfront payment of $11M plus up to $11M regulatory milestone expected in early 2026.
Also eligible for commercial milestones and mid-twenties% royalties on Japan NHI price.
Sebetralstat is an investigational oral on-demand HAE treatment; could be first oral in Japan.
Kaken will leverage regional expertise; KalVista aims for global commercial launches starting 2025.
Orphan Drug Designation received from MHLW; NDA submitted in Japan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.